Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care ...

Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

Several lines of evidence supported adding bevacizumab to platinum-containing chemotherapy. Vascular endothelial growth factor (VEGF)-A is the primary mediator of cancer growth and progression in ...

Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering ...

Corey J. Langer, MD, FACP: Personally, I believe there’s still a role for bevacizumab in select patients despite the astounding survival advantages seen with KEYNOTE-189. There are patients who ...

The value of bevacizumab in the treatment of many cancers has been questioned, given that it has been approved mostly on the basis of progression-free, and not overall, survival benefits.

Similarly, bevacizumab appeared to demonstrate improved efficacy in patients in non-Asian countries compared with patients in the Asia-Pacific region. 8 Together, these data strengthen the postulate ...

Bevacizumab is dramatically effective in recurrent glioblastoma, for which there is little other option, and this wasn't seen in breast cancer, where it was used in combinations, ...

The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer. We presently investigated the activity of bevacizumab in combination with ...

Vascular endothelial growth factor (VEGF) inhibits differentiation and maturation of dendritic cells (DC), suggesting a potential immunosuppressive role for this proangiogenic factor. Bevacizumab ...